ITM Receives Equity Investment of EUR 25 Million
February 17, 20226 min
Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITMās Targeted Radionuclide Therapeutic and Diagnostic candidates for Greater China ITM Isotope Technologies Munich SEĀ (ITM), a leading radiopharmaceutical biotech company andĀ Grand Pharmaceutical Group LimitedĀ (GP), a diversified global pharmaceutical company listed in Hong Kong, today announced...